In 2025, Cellectis will continue to focus its efforts and expenses on advancing its core clinical trials BALLI-01 and NATHALI ...

Alumni of government schools in Dunyapur have donated Rs2 million, pledged to construct additional classrooms, and announced ...

Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, ...

Rare diseases - a medical condition so obscure that even your doctor has to Google. Despite their name, these diseases ...